Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $115.00 target price on the biopharmaceutical company’s stock. RARE has been the topic of a number of other research reports. Stifel Nicolaus increased […]

Leave a Reply

Your email address will not be published.

Previous post Seagate Technology (NASDAQ:STX) PT Raised to $125.00
Next post Comerica (NYSE:CMA) Downgraded to “Hold” at Truist Financial